3-hr Virtual Seminar: IND Applications for Phase I Studies
October 19, 2012 - Palo Alto CA US
This 3-hr virtual seminar will review FDA’s IND requirements for Phase I and First-in-Man (FIM) clinical trials. It will cover the structure of an IND document and discuss granular and sectional IND creation strategies and practical approaches for an IND submission. Why Should You Attend: All sponsors of clinical trials in the US for drug and biologics have to first file an Investigational New Drug (IND) application with the FDA containing extensive information in support of the proposed clinical trial. The IND application contains all available preclinical and clinical testing information, and all manufacturing information for the investigational product, along with clinical protocol, informed consent template, investigator’s brochure and other relevant information. These requirements are particularly tough for sponsors of Phase I and First-in-Man (FIM) clinical trials since these trials are usually planned early on in the development phase with limited preclinical information and may use a preliminary formulation of the investigational product.